Ivabradina Teva (Ivabradine)

Ivabradine selectively inhibits the funny (If) current in the sinoatrial node, the electrical signal that initiates each heartbeat. Blocking this current slows the pacemaker activity, resulting in a lower heart rate while leaving contractility and blood pressure largely unchanged.

The dose of ivabradine is individualized by the prescribing clinician based on the patient’s resting heart rate, clinical condition, and response to therapy. The prescriber determines the appropriate strength, frequency, and any necessary titration.

The safety of ivabradine during pregnancy and lactation has not been established. It is classified as having an unknown pregnancy category, and use is generally avoided unless the potential benefit justifies the potential risk to the fetus. Breastfeeding is not recommended because the drug may pass into milk.

To request Ivabradina Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Both ivabradine and beta‑blockers lower heart rate, but ivabradine does so by directly inhibiting the If current without affecting beta‑adrenergic receptors. This means it does not influence blood pressure or contractility, making it useful when beta‑blockers are contraindicated or insufficient. However, beta‑blockers also provide anti‑arrhythmic and anti‑ischemic benefits that ivabradine lacks.

Ivabradina Teva tablets should be stored at temperatures below 25 °C, in their original container, and protected from moisture and direct sunlight. Keep the product out of reach of children and avoid storing in bathrooms or other humid environments.

The medication is taken orally as a whole tablet, with or without food, according to the prescriber’s instructions. Patients should swallow the tablet with water and avoid crushing or chewing it, as this could affect the drug’s release profile.

The most concerning adverse events include symptomatic bradycardia, atrial fibrillation, severe hypotension, and visual loss (including luminous phenomena). Patients should be monitored for these events, especially when combined with other heart‑rate‑lowering agents or in those with pre‑existing conduction disorders.

Ivabradine is contraindicated in patients with severe sinus bradycardia (resting heart rate <50 bpm), sick sinus syndrome, second‑ or third‑degree atrioventricular block, acute decompensated heart failure, and in those taking strong CYP3A4 inhibitors that could raise drug levels. It should also be avoided in individuals with known hypersensitivity to ivabradine.